Junshi TIGIT single resistance approved clinically

On January 27th, Regency Bio announced that its application for clinical trial of anti-TIGIT monoantigen JS006 injection had been approved by NMPA.
used to conduct research on the treatment of advanced solid tumors.
TIGIT (T-cell immunoglobulin and TIIM domain) is a common inhibitory subject of emerging NK cells and T-cells that binds to highly expressed PVR subjects on tumor cells and mediates inhibitory signals of immune response, directly inhibiting the killing of tumor cells by NK cells and T-cells, similar to PD-1 inhibition of T-cells.
JS006 is a specific anti-TIGIT monoclonal antibody injection developed by Junshi.
preclinical results show that JS006 can specific block TIGIT-PVR inhibition path, stimulate the activity of lethal immune cells, secrete tumor killer factors.
preclinical trials have shown that anti-TIGIT antibodies and anti-PD-1/PD-L1 antibodies can act in synergetic anti-tumor effects.
combination of the two is a promising cancer treatment strategy that promises to increase patient response to immunotherapy and expand the range of people who may benefit.
, there are no similar target products at home and abroad have been approved for listing.
, four domestic enterprises have carried out TIGIT antibody clinical research, of which Roche's Tiragolumab progress is the fastest, has been in Phase III research stage.
Xinda, Baiji, Junshi is the fastest pace of development of domestic enterprises.
Medicine Rubik's Cube Source: Pharmaceutical Rubik's Cube Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mace Medical and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here